header-logo header-logo

28 February 2014 / Sarah Moore
Issue: 7596 / Categories: Features , Regulatory
printer mail-detail

A bitter pill?

What impact will the new European Medical Device Regulations have on UK medicine, asks Sarah Moore

At the end of last year, after a year of fierce lobbying by patient groups and manufacturers alike, the new European Medical Device Regulations were finally submitted to the European Parliament and Council for debate and member state approval. When implemented, these new regulations will change legislation that has remained largely untouched for over 20 years.

Ongoing, high profile, prosthetic hip and breast implant litigation has played a key role in galvanising this change. However, exactly what impact these proposed regulatory changes will have, both for patient safety and product litigation in the UK remains to be seen.

EUCOMED, the organisation which speaks for European medical device manufacturers, has warned that the new regulations will stifle innovation and slow down the release of novel products into the market. For product liability lawyers, and others dealing with the after-effects of “novel” products, such as the ASR hip prosthesis, this change in pace has the potential at least to better protect product users across Europe. However, the extent to which

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

Jurit LLP—Caroline Williams

Jurit LLP—Caroline Williams

Private wealth and tax team welcomes cross-border specialist as consultant

Freeths—Michelle Kirkland Elias

Freeths—Michelle Kirkland Elias

International hospitality and leisure specialist joins corporate team as partner

Flint Bishop—Deborah Niven

Flint Bishop—Deborah Niven

Firm appoints head of intellectual property to drive northern growth

NEWS
Talk of a reserved ‘Welsh seat’ on the Supreme Court is misplaced. In NLJ this week, Professor Graham Zellick KC explains that the Constitutional Reform Act treats ‘England and Wales’ as one jurisdiction, with no statutory Welsh slot
The government’s plan to curb jury trials has sparked ‘jury furore’. Writing in NLJ this week, David Locke, partner at Hill Dickinson, says the rationale is ‘grossly inadequate’
A year after the $1.5bn Bybit heist, crypto fraud is booming—but so is recovery. Writing in NLJ this week, Neil Holloway, founder and CEO of M2 Recovery, warns that scams hit at least $14bn in 2025, fuelled by ‘pig butchering’ cons and AI deepfakes
After Woodcock confirmed no general duty to warn, debate turns to the criminal law. Writing in NLJ this week, Charles Davey of The Barrister Group urges revival of misprision or a modern equivalent
Family courts are tightening control of expert evidence. Writing in NLJ this week, Dr Chris Pamplin says there is ‘no automatic right’ to call experts; attendance must be ‘necessary in the interests of justice’ under FPR Pt 25
back-to-top-scroll